I can understand the frustrations of people who have invested in AT1 and not seeing the SP move north and want to see big numbers, agreements and multiple anns. But remember AT1 is an OEM manufacturer with a global foot print. B2B and B2C business model. All the comparisons made here seem to be apples and pears arguments. Rome wasn't built in a day and the rapid testing business is here to stay. Just be happy that flooding the market with rdt products and pushing approvals from all angles going up to federal policy making ie medicare rebates is going to upset the business models of big pathology businesses. This is great for AT1. Chess not checkers.
I can understand the frustrations of people who have invested in...
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
0.001(3.33%) |
Mkt cap ! $19.81M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.1¢ | 2.9¢ | $4.745K | 159.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 123968 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 53324 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.1¢ |
Change
0.001 ( 3.33 %) |
||||
| Open | High | Low | Volume | ||
| 3.0¢ | 3.1¢ | 2.9¢ | 32795 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| AT1 (ASX) Chart |